Clinical Trial: Polypectomy in Patients Taking Dual Antiplatelet Agents

Study Status: Enrolling by invitation
Recruit Status: Enrolling by invitation
Study Type: Interventional

Official Title: Effects of Antiplatelets Discontinuation in Patients Receiving Polypectomy: Randomized Controlled Trial

Brief Summary: Current guidelines recommend discontinuation of antiplatelets (i.e clopidogrel) for 7 days in patients taking DAT (dual antiplatelet therapy) before colonoscopy and polypectomy. The purpose of this study was to examine if a) discontinuation of these drugs reduces bleeding risks during polypectomy and if b) discontinuation of these drugs increases the occurence of thromboembolic events.

Detailed Summary: Patients taking dual antiplatelets (DAT) and who visited for colonoscopy were eligible for enrollment in this study. On enrollment, patients were randomized to two groups. One group continued DAT and the other group discontinued antiplatelets (i.e. clopidogrel, ticagrelor, prasugrel) for 7 days before colonoscopy. If polyps (≤1 cm) were observed during colonoscopy, they were removed by cold snare polypectomy. The primary aim was to compared the delayed bleeding rates of the two groups.
Sponsor: Incheon St.Mary's Hospital

Current Primary Outcome: Delayed bleeding requiring hemostasis after polypectomy [ Time Frame: 2 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: immediate bleeding requiring hemostasis after polypectomy [ Time Frame: 1 day ]

Original Secondary Outcome: Same as current

Information By: Incheon St.Mary's Hospital

Dates:
Date Received: August 1, 2016
Date Started: January 2016
Date Completion: March 2019
Last Updated: August 16, 2016
Last Verified: August 2016